Literature DB >> 2004630

Plasma antiepileptic drug concentrations during pregnancy.

C M Lander1, M J Eadie.   

Abstract

Steady-state plasma antiepileptic drug (AED) concentrations were measured at intervals throughout pregnancy and during the postnatal period in 105 women who underwent 134 pregnancies. Phenytoin (PHT) dosage had to be increased in 85% of pregnancies in which the drug was received, carbamazepine (CBZ) dosage in 70%, and phenobarbital (PB) or methylphenobarbital (MPB) dosage in 85%, in an attempt to prevent or correct a fall in plasma concentrations of the respective drugs as pregnancy progressed. The altered disposition of the AEDs usually began in the first 10 weeks of pregnancy (often before epileptic pregnant women are referred for neurological supervision), and had returned to baseline value within 4 weeks of childbirth in two thirds of the women receiving PHT. The return to the nonpregnant situation appeared to be slower for CBZ, PB, and MPB. In women studied during more than one pregnancy, the changes in AED dosage to plasma concentration ratios tended to be greater in the first than in the subsequent pregnancies. Full seizure control prior to pregnancy was associated with a more favorable outcome for freedom from seizures during pregnancy. However, the plasma level monitoring-dosage adjustment policy produced no marked improvement in overall seizure control in pregnancy. This may have occurred because some patients were seen too late in their pregnancies for the policy to have been applied optimally.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2004630     DOI: 10.1111/j.1528-1157.1991.tb05253.x

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  9 in total

1.  Changes in maternal liver Cyp2c and Cyp2d expression and activity during rat pregnancy.

Authors:  Leslie J Dickmann; Suzanne Tay; Tauri D Senn; Huixia Zhang; Anthony Visone; Jashvant D Unadkat; Mary F Hebert; Nina Isoherranen
Journal:  Biochem Pharmacol       Date:  2008-02-07       Impact factor: 5.858

Review 2.  Therapeutic monitoring of antiepileptic drugs during pregnancy and in the postpartum period: is it useful?

Authors:  Naghme Adab
Journal:  CNS Drugs       Date:  2006       Impact factor: 5.749

Review 3.  Pharmacotherapy for mood disorders in pregnancy: a review of pharmacokinetic changes and clinical recommendations for therapeutic drug monitoring.

Authors:  Kristina M Deligiannidis; Nancy Byatt; Marlene P Freeman
Journal:  J Clin Psychopharmacol       Date:  2014-04       Impact factor: 3.153

Review 4.  Treatment of epilepsy in women of reproductive age: pharmacokinetic considerations.

Authors:  James W McAuley; Gail D Anderson
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

Review 5.  Gender effects in pharmacokinetics and pharmacodynamics.

Authors:  R Z Harris; L Z Benet; J B Schwartz
Journal:  Drugs       Date:  1995-08       Impact factor: 9.546

Review 6.  Management of epilepsy during pregnancy.

Authors:  Dina Battino; Torbjörn Tomson
Journal:  Drugs       Date:  2007       Impact factor: 9.546

7.  Phenytoin metabolism during pregnancy.

Authors:  M J Eadie; G E McKinnon; R G Dickinson; W D Hooper; C M Lander
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

Review 8.  Pharmacokinetic data in pregnancy: A review of available literature data and important considerations in collecting clinical data.

Authors:  Paola Coppola; Essam Kerwash; Janet Nooney; Amro Omran; Susan Cole
Journal:  Front Med (Lausanne)       Date:  2022-10-04

Review 9.  Pregnancy and the Control of Epileptic Seizures: A Review.

Authors:  Mervyn J Eadie
Journal:  Neurol Ther       Date:  2021-05-14
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.